Cyclosporine A (CsA) immunosuppressive treatment has become an adjunctive therapy in neural transplanta tion of dopamine-secreting cells for treatment of Parkinson's disease (PD). Recently, CsA and its analogues have been shown to promote trophic effects against neurodegenerative disorders, and therefore CsA may have direct beneficial effects on dopaminergic neurons and dopamine-mediated behaviors. The present study examined the interaction between the reported CsA-induced hyperactivity and the possible alterations in nigral tyrosine hydroxylase (TH)-immunoreactive neurons in rats with damaged blood-brain barrier. CsA was administered at a therapeutic dose (10 mg/kg/day, IP, for 9 days) used in neural transplantation protocol for PD animal models. CsA-treated animals displayed significantly higher general spontaneous locomotor activity than control animals at drug injection days 7 and 9. Histological assays at day 9 revealed that there was a significant increase in TH-immunoreactive neurons in the nigra of CsA-treated rats compared to that of the vehicle-treated rats. The nigral TH elevation was accompanied by suppressed calcium-phosphotase calcineurin activity, indicating an inhibition of host immune response. This is the first report of CsA exerting simultaneous immunosuppressive and neurotrophic effects, as well as increasing general spontaneous loco motor behavior. These results support the utility of CsA as a therapeutic agent for PD and other movement disorders.
INTRODUCTION
Clinical trials of neural transplantation of fetal dopa mine (DA)-secreting cells with adjunctive cyclosporine A (CsA) immunosuppressive therapy have been initiated recently as an experimental treatment for Parkinson's disease (PD). The enhancement of DA levels and the subsequent amelioration of parkinsonian symptoms in transplanted patients, as well as in transplanted parkin sonian animals, have been attributed solely until now to the grafted tissue (1, 17) . The direct effects of CsA on transplant recipients is not well documented. Recent studies have added "neuroprotective" (19, 26) and "be havioral" (4-7) roles to the primary immunosuppressive effects of CsA. In view of the reported CsA-induced effects on the nigrostriatal DA pathway (the primary area that degenerates in PD), it is possible that CsA di rectly contributes to the observed neuroprotection or re generation of the nigral DA neurons following brain in sults.
To date, only a few studies have examined the involvement of CsA in neurodegeneration and regenera tion. We reported recently behavioral alterations in nor mal (5) and hemiparkinsonian (6) rats following chronic administration of CsA. However, in both studies, we could not detect any alterations in the levels of striatal DA and its metabolites using HPLC. Previous studies have noted increments in DA following injection of fairly high doses of CsA (>20 mg/kg) (11, 23) . These observations suggest that CsA poorly crosses the bloodbrain barrier (BBB) at low doses, and indeed it has been shown that CsA is more potent in the plasma than in the brain (2) . Accordingly, a damaged BBB may enhance CsA entry into the brain. Of note, a compromised BBB accompanies the early stages of neural transplantation surgery.
In the present study, we investigated the CsA-induced neurotrophic effect on the nigral DA neurons in rats that did not receive transplants, but with a damaged BBB. Destruction of the BBB was accomplished by bi lateral stereotaxic injections of saline through an 18gauge needle. Brundin (8) and others (20, 21) have estab lished that such intraparenchymal insults, including the neural grafting surgery, can compromise the BBB for 9-12 days, and thus the 9-day period of BBB breakdown was chosen for CsA daily injection in the present study. During this CsA regimen, the spontaneous locomotor activity of CsA-treated animals was examined, and fol lowing the drug regimen, we assessed tyrosine hydroxy lase (TH; the main rate-limiting enzyme for DA) immu noreactivity in the substantia nigra (SN). To evaluate the entry of CsA into the CNS, the calcium-phosphotase calcineurin (CN) immunoreactivity was evaluated. It has been established previously that CsA inhibits CN ex pression to exert its immunosuppressive effect (28, 29) .
Because the striatum has been demonstrated as the spe cific brain area of high CN expression in normal rats (13) and CsA was shown to inhibit CN expression (30), we chose this region for assessment of CsA-mediated immunosuppresion in the brain.
We report here, for the first time, that CsA-treated animals displayed hyperactivity coupled with increased expression of nigral TH immunoreactivity and with cor responding decrement in CN immunoreactivity, suggest ing simultaneous induction of trophic action and immu nosuppression mediating the CsA effect on locomotor behavior.
MATERIALS AND METHODS

Subjects
Twelve female Wistar rats (240-320 g) served as subjects. Food and water were freely available in their living cages. A reversed 12-h light/12-h dark cycle was administered by artificial illumination and experiment was carried out during the dark period. The room tem perature was maintained at 25°C.
Surgical Disruption of BBB
The animals were initially anesthetized with ketamine (60 mg/kg, IP) and placed in a stereotaxic appara tus. Xylocaine (10 mg/kg) was injected into the incision site. Physiological saline (0.025 ml/site) was injected through a microsyringe (needle diameter = 0.5 mm) bi laterally targeting the striatum (from bregma: AP= 1.5, ML = 2.6, DV = 6.0 mm) (23) .
Pharmacological Treatment
CsA (Sigma Pharmaceuticals, 10 mg/kg, IP) was in jected daily for 9 days. The volume was 2 ml/kg. The same volume of peanut oil was injected to the control group. Following stereotaxic surgery to break the BBB, the animals were then randomly assigned to experimen tal or control treatment condition. The experimental group (n = 8) received daily injection of CsA starting on the day of the surgery, whereas the control group (n = 4) received daily injection of peanut oil, which was the vehicle used for CsA. Both groups of animals were used also in a separate experiment investigating the effects of CsA on memory retention of a passive avoidance task (7) .
Digiscan Recording of Spontaneous Locomotor Activity
At days 0 (surgical procedure), 5, 7, and 9, animals were individually placed in the Digiscan locomotor ac tivity chambers. The Digiscan computerized analyzer was programmed to collect data at 1-h intervals over a period of 10 h. The first hour was allotted for habitua tion of the animal to the apparatus. The peak horizontal activity was identified for each animal and used as raw data to analyze differences across treatment groups.
Histology
All animals were sacrificed on the day following the last drug administration. Animals were deeply anesthe tized and perfused intracardiacally with 150 ml saline followed by 150 ml of 4% paraformaldehyde. The brains were postfixed overnight in 4% paraformaldehyde and subsequently immersed in 20% sucrose in 4% parafor maldehyde and stored at 8°C until sectioning. A vibrotome (Vibroslice, FL) was used to cut the brain (40-|im sections). Immunohistochemical assessment of nigral DA neurons was carried out by staining sections through the midbrain. Six serial sections of the SN (correspond ing to atlas sections between 5.0 and 5.2 mm posterior to bregma) (23) were processed for TH immunohistochemistry. Sections were preincubated in 5% blocking serum (normal goat, Jackson ImmunoResearch Labora tories, PA) in 0.1% Triton X in 0.1 M NaPBS for 60 min, followed by incubation in the primary antibody (Eugene Tech International, NJ; 1:1000 dilution in 0.1 M phosphate-buffered saline, NaPBS) at room tempera ture overnight. The sections were reacted with the ap propriate biotinylated secondary antibody (1:2000) for 45 min, followed by an avidin-biotin-peroxidase com plex system (ABC Elite Vectastain Kit, Vector, Burlingame, CA) for 45 min. Finally, the Vector VIP Kit (Vec tor) was used to visualize the reaction product. The sections were mounted on gelatin-coated glass slides, dried overnight, dehydrated in increasing alcohol con centrations, and coverslipped using Permount mounting solution.
Serial sections were digitized using a PC-based Im age Tools computer program. To determine the degree of CsA-induced alteration in the midbrain, the total number of TH-immunoreactive (ir) nigral neurons was counted on both sides of the midbrain. We classified TH-ir neurons in the SN pars compacta according to the previously described criteria (15) . The main criterion for delineating the SN from the ventral tegmental area was the localization of the oculomotor nerve root, which places the SN laterally relative to the root. Comparisons of mean total nigral TH-ir neurons from CsA-treated an imals and that from vehicle-treated animals were con ducted.
To determine the degree of CN inhibition by CsA, brain sections that included the septal region (+1.4 to +0.2 mm from bregma) (23) were immunostained with CN (Chemicon, 1:10,000). Ten serial sections per ani mal were processed using the procedures described above except that the CN, instead of TH, primary anti body was used.
Statistical Analysis
Two observers blind to treatment conditions carried out the cell counts and qualitative assessments of TH and CN immunoreactivity. Multifactorial ANOVA with post hoc Bonferroni/Dunn compromised /-tests were used to reveal statistical significance between CsA-and vehicle-treated groups.
RESULTS
Hyperactivity in CsA-Treated Rats
Animals that received CsA treatment exhibited sig nificantly increased locomotor behavior (Fig. 1A) . ANOVA revealed significant main effects of the drug, F(l, 10) = 19.41, and the time, F(3, 44) = 13.28. Hori zontal activity was used as representative parameter of general spontaneous behavior, and significant incre ments in locomotor activity (ps < 0.001) were noted at days 7 and 9 in CsA-treated rats compared to vehicletreated rats (Fig. IB) . In addition, within-group compari sons revealed that the CsA-treated rats displayed a sig nificant increase in locomotor behavior at days 7 and 9 (ps < 0.001) compared to earlier test periods (days 0 and 5). In contrast, vehicle-treated rats did not show any sig nificant alterations in their locomotor behavior through out the experiment.
Increased TH Immunoreactivity in CsA-Treated Rats
The animals that were treated with CsA had a small, but significant, increase in nigral TH-ir neurons (33.51 120 Figure 1 . Increments in horizontal activity and in TH immu noreactivity in CsA-treated rats. Animals that received CsA injections exhibited a significant increase in locomotor activity (data are expressed as means ± SEM on test days 7 and 9 com pared to control animals (A). Histological examinations at day 9 revealed that the observed behavioral change was accompa- (Fig. 2) . The TH immunoreactivity in the SN of animals subjected to the stereotaxic surgeryinduced BBB breakdown and subsequently treated with peanut oil was comparable with that of control, normal animals as previously reported (16, 19) . Of interest, the animals that received CsA exhibited an obvious increase in the density of the TH-ir fibers in the three major sub divisions of the SN, namely, pars compacta, pars reticu lata, and pars lateralis. A band of dense TH-ir fibers can be seen to form along the pars compacta as well as the pars reticulata. Futhermore, we noted a denser network of TH-ir fibers crossing between the pars compacta and the pars reticulata of animals treated with CsA. These results indicate that CsA increased the TH immunoreac tivity in the SN. Correlational analyses between locomo tor activity (at day 9) and TH immunoreactivity in CsA-treated animals revealed a high positive correlation (R 1 = 0.936) (Fig. 1C ).
Depressed CN Expression in CsA-Treated Rats
Assessment of CN expression in the striatum re vealed an almost absent CN expression in the CsAtreated animals compared to that of vehicle-treated ani mals (Fig. 3) . In animals that received the vehicle treat ment, darkly stained CN-ir cells were noted in the stria tum. Many dendritic processes can be seen arising in most of the CN-ir cells and these formed dense networks of CN-ir fibers. In contrast, the animals that received CsA treatment showed a marked decrease in CN activity in the striatm as revealed by almost total absence of im munoreactivity of the somas, severe pruning of most dis tal dendritic processes, and reduction in the density of network of CN-ir fibers. The CN immunoreactivity was 
DISCUSSION
The present study demonstrated that hyperactive ani mals that received chronic systemic injections of CsA exhibited increments of TH immunoreactivity in the SN compared to vehicle-treated rats. The increased locomo tor behavior and elevated nigral TH immunoreactivity were accompanied by a significant inhibition of CN ex pression in the striatum. These results suggest that CsA exerted neurotrophic effects in addition to its immuno suppressive action to produce alteration in locomotor be havior.
Snyder and colleagues (28, 29) reported recently that nonimmunosuppressive analogues of immunosuppres sive drugs FK506, rapamycin, and CsA can produce neurotrophic effects in vitro and enhance functional and morphological recovery in rats with sciatic nerve crush. Isacson and colleagues (10) also demonstrated in vitro and in vivo neurotrophic effects of an immunosuppres sant analogue on DA neurons. Previously, we demon strated that CsA can increase general spontaneous loco motor activity in normal (5) or hemiparkinsonian rats (6) . In addition, we showed recently that memory reten tion was not impaired in rats chronically injected with CsA, and these animals even appeared to perform better in a passive avoidance task compared to normal animals (7) . The present results support those of Snyder and col-leagues as well as recent studies showing that immuno suppressants, including CsA and FK506, may promote neuroprotective effects against ischemia (26) and MPTP-or 6-OHDA-induced neurodegeneration (16, 20) . These observations may have direct influence on neural transplantation therapy because immunosuppres sant treatment has become an adjunctive therapy for transplantation. Because normalization of locomotor functions is the major index of successful neural trans plantation in neurodegenerative disorders, such as PD and Huntington's disease, delineation between direct im munosuppressant effects from those of the genuine "treatment" needs to be determined to test the validity of such therapy. Furthermore, the locomotor behaviors altered by CsA are DA-mediated behaviors (4) (5) (6) . Thus, DA replacement therapy, such as the neural transplanta tion of DA-secreting cells, may be enhanced by CsA treatment. The present observation that CsA treatment alone induced an increase in nigral TH immunoreactiv ity suggests that careful interpretation of data, as well as adding appropriate controls (i.e., CsA treatment-alone subjects) need to be considered when contemplating with neural transplantation with CsA adjunctive therapy for treatment of PD.
In our previous studies (5, 6) , we did not detect incre ments in DA and its metabolites following chronic CsA immunosuppression. Because we previously used ani mals with intact BBB, the present animals with damaged BBB might have promoted better access of CsA into the brain and thereby affected the DA neurons directly. These observations suggest that CsA, which poorly per meates the BBB, needs to become accessible in the brain to exert its effects on DA neurons. Higher doses of CsA have been demonstrated also to increase DA levels in many regions of the brain of animals with intact BBB (11, 24) . Furthermore, in animal models of neurotoxicinduced (thus compromising the BBB) neurodegenera tion, CsA has been shown to be effective in protecting DA neurons against excitotoxicity (16, 26) .
Immunosuppressants may exert their therapeutic ef fects on early calcium regulatory steps in the immune response (28, 29) . In the present study, we demonstrated that CsA-treated animals with their BBB damaged stereotaxically (which simulates the neural transplantation protocol but with the graft withheld) had significantly suppressed expression of calcium-calmodulin-dependent phosphotase CN in the striatum. These findings con firmed previous reports (13, 30) noting suppressed CN expression following chronic immunosuppression in normal animals with intact BBB. Of note, the observed suppression of CN expression in our study was accom panied by an increase in the density of nigral-immunoreactive fibers for TH. To the best of our knowledge, this is the first report of CsA-induced CN inhibition with simultaneous enhancement of TH immunoreactivity. One may assume then that the marked reduction in CN expression predisposed enhancement of TH immunore activity. Indeed, CN activity inhibition was suggested to modulate the neurological effects of CsA (3).
In the studies by Snyder and colleagues (28, 29) and by Isacson and colleagues (10), however, neurotrophic effects and functional recovery were achieved using nonimmunosuppressive ligands that, of course, do not render immunosuppression, indicating that the observed beneficial effects are independent of direct effects of im munosuppression or inhibition of CN activity. It is pos sible that in addition to suppressing CN activity in the CNS, as we noted in the present chronic CsA treatment (27) , neurobehavioral effects by immunosuppressants and their ligands may be mediated by their stimulatory effects on other factors such as trophic factors (28, 29) . Indeed, CsA was shown to interact with the neurotrophic factor transforming growth factor (TGF)-pl (22) . Of note, GDNF, a member of the TGF-p family, has re cently been demonstrated as the most potent selective DA neurotrophic factor and thus a possible therapeutic agent for PD (9, 12, 18) . Investigations on possible inter actions between CsA and known neurotrophic factors may result in better understanding of CsA's mechanism of action. Furthermore, it has been suggested that CsA inhibits nitric oxide synthase, which is one of the postu lated underlying factors for the occurrence of parkinso nian symptoms (14, 25) .
Chronic CsA administration, however, entails some neurologic side effects (4, 11, 24) . The demonstration of neurobehavioral beneficial effects using nonimmuno suppressive drugs (10, 28, 29) , which obviously would avoid deleterious side effects associated with chronic immunosuppression, is a step towards establishing "immunotrophic" drugs as efficacious therapeutic agents for CNS diseases. Alternatively, adjustment of dosing regi men of CsA may promote trophic effects with no ob servable side effects, as seen in the present study. The accumulating evidence of neuroprotective effects of im munosuppressants and their ligands warrants further in vestigation of their mechanisms of action to exploit the efficacy of these drugs on ameliorating cellular and be havioral dysfunctions associated with neurodegenerative disorders.
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